

Senate Bill 287

By: Senators James of the 35th and Scott of the 36th

A BILL TO BE ENTITLED
AN ACT

1 To amend Title 31 of the Official Code of Georgia Annotated, relating to health, so as to
2 provide a short title; to provide for legislative purpose; to provide definitions; to establish an
3 Rx Program within the Department of Medical Assistance to lower prescription drug prices
4 for uninsured and underinsured residents of the state; to provide for discounted prices for Rx
5 Program participants; to provide for eligibility of individuals to participate in the Rx
6 Program; to provide for operation of the Rx Program; to provide for resolution of
7 discrepancies in rebate amounts; to provide for an Rx Dedicated Fund; to provide for an
8 annual report to the General Assembly; to authorize the Department of Human Resources to
9 adopt implementive rules; to authorize waivers of federal law; to provide for other matters
10 relative to the foregoing; to repeal conflicting laws; and for other purposes.

11 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

12 style="text-align:center">**SECTION 1.**

13 Title 31 of the Official Code of Georgia Annotated, relating to health, is amended by adding
14 at the end a new chapter to read as follows:

15 style="text-align:center">"CHAPTER 46

16 31-46-1.

17 This chapter shall be known and may be cited as the 'Georgia Prescription Drug Fair
18 Pricing Act.'

19 31-46-2.

20 It is the intention of the General Assembly to create a program whereby the state acts as
21 a participant in the prescription drug marketplace, negotiating voluntary rebates from drug
22 companies and using the funds to make prescription drugs more affordable to residents of
23 this state. Such a program will improve public health and welfare, promote the economic

1 strength of our society, and substantially benefit state health assistance programs, including
2 the Medicaid program.

3 31-46-3.

4 As used in this chapter, the term:

5 (1) 'Commissioner' means the commissioner of medical assistance.

6 (2) 'Department' means the Department of Medical Assistance.

7 (3) 'Labeler' means an entity or person that receives prescription drugs from a
8 manufacturer or wholesaler and repackages those drugs for later retail sale, and that has
9 a labeler code from the federal Food and Drug Administration under 21 Code of Federal
10 Regulations, 207.20 (1999).

11 (4) 'Manufacturer' means a manufacturer of prescription drugs and includes a subsidiary
12 or affiliate of a manufacturer.

13 (5) 'Retail pharmacy' means a retail pharmacy or other business licensed to dispense
14 prescription drugs in this state.

15 31-46-4.

16 (a) An Rx Program is established within the department to lower prescription drug prices
17 for uninsured and underinsured residents of the state.

18 (b) A drug manufacturer or labeler that sells prescription drugs in the state may voluntarily
19 elect to enter into a rebate agreement with the department.

20 (c) The commissioner shall negotiate the terms of the rebate from a manufacturer or
21 labeler, taking into consideration the rebate calculated under the Medicaid Rebate Program
22 pursuant to 42 United States Code, Section 1396r-8, the average wholesale price of
23 prescription drugs, and any other available information on prescription drug prices and
24 price discounts.

25 (d) If a drug manufacturer or labeler elects not to agree to a rebate, the commissioner may
26 place those manufacturer's or labeler's products on the prior authorization list for the state
27 Medicaid program and take similar actions involving prior authorization or formularies for
28 any other state funded prescription drug program. The commissioner shall promulgate
29 rules creating clear procedures for the implementation of this subsection. The names of
30 manufacturers and labelers that do not enter into rebate agreements are public information
31 and the department shall release this information to the public. The commissioner shall
32 also publicize to doctors, pharmacists, and other health professionals information about the
33 relative cost of drugs produced by manufacturers and labelers that enter into rebate
34 agreements compared to those who do not enter into rebate agreements.

1 (e) A retail pharmacy shall discount the price of prescription drugs sold to Rx Program
2 participants.

3 (1) The department shall establish discounted prices for drugs covered by a rebate
4 agreement and shall promote the use of efficacious and reduced cost drugs, taking into
5 consideration reduced prices for state and federally capped drug programs, differential
6 dispensing fees, administrative overhead, and incentive payments.

7 (2) Beginning July 1, 2001, a retail pharmacy shall offer prescription drugs at or below
8 the average wholesale price, minus 6 percent, plus a dispensing fee designated by the
9 commissioner. These initial price levels shall be calculated by the commissioner and the
10 dispensing fee shall not be less than that provided under the state Medicaid program. The
11 average wholesale price is the wholesale price charged on a specific commodity that is
12 assigned by the drug manufacturer and is listed in a nationally recognized drug pricing
13 file.

14 (3) No later than January 1, 2002, a retail pharmacy shall offer prescription drugs at or
15 below the initial price levels specified in paragraph (2) minus the amount of any rebate
16 paid by the state to the retail pharmacy. These discounted price levels shall be calculated
17 by the commissioner. In determining the discounted price levels, the commissioner shall
18 consider an average of all rebates weighted by sales of drugs subject to these rebates over
19 the most recent 12 month period for which the information is available.

20 (f) All residents of the state are eligible to participate in the Rx Program. The department
21 shall establish simplified procedures for issuing Rx Program enrollment cards to eligible
22 residents. The department shall undertake outreach efforts to build public awareness of the
23 Rx Program and maximize enrollment by eligible residents.

24 (g)(1) The department shall adopt rules requiring disclosure by retail pharmacies to Rx
25 Program participants of the amount of savings provided as a result of the Rx Program.
26 The rules must protect information that is proprietary in nature.

27 (2) The department may not impose transaction charges on retail pharmacies that submit
28 claims or receive payments under the Rx Program.

29 (3) A retail pharmacy shall submit claims to the department to verify the amount charged
30 to Rx Program participants.

31 (4) On a weekly or biweekly basis, the department shall reimburse a retail pharmacy for
32 discounted prices provided to Rx Program participants and dispensing fees set by the
33 commissioner.

34 (5) The department shall collect from the retail pharmacies utilization data necessary to
35 calculate the amount of the rebate from the manufacturer or labeler. The department shall
36 protect the confidentiality of all information subject to confidentiality protection under
37 state or federal law, rule, or regulation.

1 (h) Discrepancies in rebate amounts shall be resolved using the process established in this
2 subsection.

3 (1) If there is a discrepancy in the manufacturer's or labeler's favor between the amount
4 claimed by a pharmacy and the amount rebated by the manufacturer or labeler, the
5 department, at the department's expense, may hire a mutually agreed upon independent
6 auditor. If a discrepancy still exists following the audit, the manufacturer or labeler shall
7 justify the reason for the discrepancy or make payment to the department for any
8 additional amount due.

9 (2) If there is a discrepancy against the interest of the manufacturer or labeler in the
10 information provided by the department to the manufacturer or labeler regarding the
11 manufacturer's or labeler's rebate, the manufacturer or labeler, at the manufacturer's or
12 labeler's expense, may hire a mutually agreed upon independent auditor to verify the
13 accuracy of the data supplied to the department. If a discrepancy still exists following the
14 audit, the department shall justify the reason for the discrepancy or refund to the
15 manufacturer any excess payment made by the manufacturer or labeler.

16 (3) Following the procedures established in paragraph (1) or (2) of this subsection, either
17 the department or the manufacturer or labeler may request a hearing. Supporting
18 documentation shall accompany the request for a hearing.

19 (i) The Rx Dedicated Fund is established to receive revenue from manufacturers and
20 labelers who pay rebates and any appropriations or allocations designated for the fund. The
21 purposes of the fund are to reimburse retail pharmacies for discounted prices provided to
22 Rx Program participants, and reimburse the department for the costs of administering the
23 program, including contracted services, computer costs, professional fees paid to retail
24 pharmacies, and other reasonable program costs. The Rx Dedicated Fund is a nonlapsing
25 dedicated fund. Interest on Rx Dedicated Fund balances accrues to the fund.

26 (j) The department shall report the enrollment and financial status of the Rx Program to
27 the General Assembly by the second week in January each year.

28 (k) In implementing this chapter, the department shall coordinate with other governmental
29 programs to increase efficiency and, where it is beneficial to another state program,
30 combine drug pricing negotiations to maximize drug rebates for this and other programs,
31 including the state Medicaid program.

32 (l) The department may adopt rules to implement the provisions of this chapter.

33 (m) The department may seek any waivers of federal law, rule, or regulation necessary to
34 implement the provisions of this chapter."

35 SECTION 2.

36 All laws and parts of laws in conflict with this Act are repealed.